Ambenonium chloride information

Ambenonium chloride
Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a699058
Routes of; administration	Oral
ATC code	N07AA30 (WHO) ;
Pharmacokinetic data
Bioavailability	Low
Identifiers
	IUPAC name 2,2'-[(1,2-Dioxoethane-1,2-diyl)diimino]bis[N-(2-chlorobenzyl)-N,N-diethylethanaminium];
CAS Number	7648-98-8 ;
PubChem CID	8288;
DrugBank	DB01122 ;
ChemSpider	7987 ;
UNII	L16PUN799N;
KEGG	D01001 ;
ChEBI	CHEBI:2628 ;
ChEMBL	ChEMBL1652 ;
CompTox Dashboard (EPA)	DTXSID5048396 ;
Chemical and physical data
Formula	C28H42Cl2N4O2+2
Molar mass	537.57 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Cl-].[Cl-].Clc1ccccc1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](Cc2ccccc2Cl)(CC)CC;
	InChI InChI=1S/C28H40Cl2N4O2.2ClH/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30;;/h9-16H,5-8,17-22H2,1-4H3;2*1H ; Key:DXUUXWKFVDVHIK-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ambenonium (as ambenonium dichloride, trade name Mytelase) is a cholinesterase inhibitor^[1] used in the management of myasthenia gravis.

It is classified as a reversible cholinesterase inhibitor.^[2]

^ Bolognesi ML, Cavalli A, Andrisano V, et al. (September 2003). "Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors". Farmaco. 58 (9): 917–28. doi:10.1016/S0014-827X(03)00150-2. PMID 13679187.
^ Hodge AS, Humphrey DR, Rosenberry TL (May 1992). "Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities". Mol. Pharmacol. 41 (5): 937–42. PMID 1588924.

and 21 Related for: Ambenonium chloride information